Positron Emission Tomography Imaging Using Copper Cu 64 TP3805 in Patients With Breast Cancer

• Status: Terminated
• Trial end date: 2012-07-01
• Target enrollment: 0
• Participant gender: Female

Summary

This clinical trial studies positron emission tomography imaging in using copper Cu 64 TP3805in patients with breast cancer. Diagnostic procedures, such as positron emission tomography (PET) and positron emission mammography (PEM) scan, using Cu-64-TP3805 may help doctors find and diagnose breast cancer.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University
• Collaborator: National Institutes of Health (NIH)
• Treatments: Copper; Deoxyglucose; Fluorodeoxyglucose F18

Criteria

Inclusion Criteria:

• Female

• Breast cancer shown with abnormal mammogram and histology verification (stage-1 patients will also need to have a positive F-18-FDG whole-body scan)

• Tumor mass of 1 cm or larger, as determined by mammography, ultrasound, or magnetic resonance imaging (MRI)

• Signed informed consent form approved by the institutional review board (IRB)

Exclusion Criteria:

• Pregnant or lactating female

• Patient with asthma